H
Loading...
Loading...
Amniotic membrane wound products are 361 HCT/P biologic dressings with growth-factor and matrix content, sourced from FDA-registered banks. They are for stalled wounds, not as a first gauze.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18.
Amniotic membrane wound care dressings and products. Natural biological matrix for chronic wound healing. HCT/P compliant products from FDA-registered sources.
Amniotic wound products are 361 biologic dressings, not first-line gauze, and not automatically the same SKU as an ocular membrane. Storage follows the bank. Coverage often still wants a documented stall.
Amniotic membrane is the innermost layer of the placenta, and it possesses remarkable biological properties that support wound healing. The membrane contains over 200 growth factors, cytokines, and extracellular matrix proteins, including collagen types I, III, IV, V, and VII, fibronectin, and laminin. These components provide structural scaffolding while delivering concentrated biological signals that promote cellular migration, reduce inflammation, and inhibit scarring. Amniotic membrane also has natural antimicrobial properties and acts as a biological barrier, creating an optimal environment for wound bed preparation and tissue regeneration.
Amniotic membrane wound dressings are indicated for chronic, non-healing wounds that have not responded to standard wound care within 30 days. Common applications include diabetic foot ulcers, venous leg ulcers, pressure injuries, and post-surgical wounds. In ophthalmology, amniotic membrane has a long history of use for corneal healing. For wound care applications, the membrane is typically applied directly to a debrided wound bed and secured with a secondary dressing. Clinical evidence supports improved healing rates compared to standard care alone, particularly in wounds complicated by diabetes or vascular insufficiency.
Amniotic membrane products used in wound care are regulated under FDA's HCT/P 361 framework, which establishes requirements for donor screening, tissue processing, and product handling. All amniotic membrane products in our portfolio come from FDA-registered tissue banks that follow AATB (American Association of Tissue Banks) standards. We provide full chain-of-custody documentation, lot tracking, and storage requirements for each product. Our compliance team can guide your practice through the regulatory requirements specific to amniotic tissue products, ensuring proper handling, documentation, and billing compliance.
Do not assume an ocular amniotic product’s IFU covers a DFU. Homologous-use language is product-specific. Storage and reconstitution follow the bank, not a generic ‘keep frozen’ note.
Many CTP/skin-substitute pathways expect conservative care and serial measurements first. Amniotic membrane is not a shortcut around that sequence.
Different IFUs. Do not assume one SKU crosses.
Common coverage expectation for chronic wounds.
Per bank IFU.
Required in the 361 lane.
Contact us today to learn how Hawk Medical can support your practice.
We're not just a distributor - we're healthcare providers who understand your challenges
We own and operate medical clinics, so we understand your real-world challenges
All products meet strict regulatory requirements including HCT/P 361 compliance
Personal account management and ongoing training for your entire team
10+ years of experience helping practices implement successful programs
Learn more about related treatments, solutions, and resources
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.